TKT Asks Judge To Limit Amgen's "30 Years" EPO Exclusivity As Trial Begins

Amgen's erythropoietin patents should not translate into 30 years of Epogen exclusivity, Transkaryotic Therapies said in opening arguments May 15 in Boston federal court.